Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060720 · ClinicalTrials.gov registry record
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
A clinical trial of Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 271
- Enrollment target
- 1
- Study location
NCT03060720: Active study of Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.
NCT03060720 is a study of Pancreatic Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 271 participants, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03060720, a study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 271 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
Conditions Studied
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2026-02 |
What the registry record for NCT03060720 still lists
NCT03060720 is an observational study that tracks outcomes without assigning an intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03060720 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03060720 about?
NCT03060720 is a clinical study titled "Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy". This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
What is the current status of trial NCT03060720?
This trial is currently active not recruiting. The enrollment target is 271 participants. The study started on 2017-02-24. Estimated completion is 2026-02.
What conditions does trial NCT03060720 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
Who is sponsoring clinical trial NCT03060720?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03060720 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03060720's enrollment target sits among peer trials
271 53rd of 278 higher than 226 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03609216 · 271 participants · Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI